Converting habits of antibiotic use for respiratory tract infections in German primary care – study protocol of the cluster-randomized controlled CHANGE-3 trial by Wollny, Anja et al.
STUDY PROTOCOL Open Access
Converting habits of antibiotic use for
respiratory tract infections in German
primary care – study protocol of the
cluster-randomized controlled CHANGE-3
trial
Anja Wollny1, Attila Altiner1, Tonia Brand4, Katharina Garbe1* , Martina Kamradt5, Petra Kaufmann-Kolle4,
Mirko Leyh3, Regina Poß-Doering5, Joachim Szecsenyi5, Lorenz Uhlmann2, Arwed Voss3, Dorothea Weber2,
Michel Wensing5 and Christin Löffler1
Abstract
Background: The overuse of antibiotics is a major cause for the worldwide rise of antibiotic resistance. Although it
is well known that acute respiratory tract infections (ARTI) are mainly caused by viruses and are often self limiting,
antibiotics are too frequently prescribed in primary care. CHANGE-3 examines whether a complex intervention
focusing on improving communication and provision of prescribing feedback reduces antibiotic use in patients
suffering from ARTI.
Methods/design: The CHANGE-3 trial is a cluster-randomized controlled trial nested within a web-based public
campaign conducted in two regions in Germany. A total of 114 medical practices will be included. Practices
randomized to the intervention will receive a practice-specific antibiotic-prescription feedback and an educational
outreach visit. During the visit the whole practice team will receive an introduction to e-learning modules
addressing patient-centered communication on antibiotics. Furthermore, the practices will receive tablet PCs with
information on antibiotics and the treatment of ARTI to be presented to patients. Practices randomized to the
control will provide care as usual. The primary outcome measure is the antibiotic prescribing rate for patients with
a history of ARTI. Data collected before the intervention, during the intervention and after the intervention will be
compared. The use of narrow- vs. broad-spectrum antibiotics will be analyzed as a secondary outcome. A process
evaluation is also part of the trial.
Discussion: This study should contribute to the growing body of research on reducing antibiotic prescription.
Trial registration: ISRCTN, ISRCTN15061174. Registered retrospectively on 13 July 2018.
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Background
The excessive use of antibiotics in human and veterinary
medicine is responsible for the worldwide rise of antibiotic
resistance [1, 2]. In Germany, approximately 40–45% of all
antibiotics prescribed in human medicine stem from pri-
mary care, with acute respiratory tract infections (ARTI)
[3] being the most common cause. Although among both
experts and non-professionals it is well known that ARTI
are primarily caused by viruses and are mostly
self-limiting, in too many cases antibiotics are prescribed
[4–6]. The main reasons for the inadequate prescription
of antibiotics in primary care include a misleading safety
culture and general practitioners’ (GPs) misconception
that patients would expect an antibiotic prescription [7, 8].
This leads to over-prescribing of broad-spectrum antibi-
otics such as quinolones and cephalosporins [3]. This
eventually leads to increasing rates of antibiotic resistance,
avoidable side effects and drug interactions as well as un-
necessary direct and indirect costs, e.g., for hospital admis-
sions [9–13].
Since the 1990s, efforts to reduce unnecessary antibiotic
prescriptions in primary care have been made [3, 14]. Trials
have proven that some interventions are able to lower
medication prescription rates in a relevant manner [15, 16].
However, the effect of interventions is varying and is spe-
cific to situations and conditions [17]. A recent systematic
review on interventions aiming at reducing antibiotic pre-
scription for ARTI patients showed, for instance, positive
effects of single-element and multifaceted interventions
using GP communication skills’ training and point-of-care
testing. Other elements, such as patient-centered informa-
tion alone, had no effect [16]. Wensing et al. showed effi-
cacy of quality circles and written feedback on professional
performance and prescribing [18]. So far, most interven-
tions focus on GPs [15, 19]. Research has shown that sensi-
tizing the practice staff for a better interaction with patients
carries the potential to relieve the GP’s work and to con-
tribute to improved decision-making in general [20, 21].
Practice staff can play an important role in transferring
knowledge to patients [21]. Thus, the idea of addressing the
whole practice team in interventions to reduce unnecessary
antibiotic prescriptions is gaining momentum.
Aim
The cluster-randomized controlled CHANGE-3 trial
(cRCT) aims at testing the effect of a practice intervention
including practice-specific antibiotic-prescription feed
back, an education outreach visit, patient-centered com-
munication, and patient information on the rate of anti-
biotic prescription for ARTI in German primary care.
Patient-centered communication will be conveyed via
e-learning modules. Versions for physicians and practice
staff members will differ and will be target-
group-specific.
For the delivery of patient information, practices will
receive tablet PCs with multimedia patient information
on antibiotics and the treatment of ARTI.
The cRCT is nested within a larger-scale, web-based,
public campaign conducted in two German states and
has the title “Weniger Antibiotika: mehr Ideen” (English;
less antibiotics: more ideas) [22]. Whereas the campaign
tests the effectiveness of informing the patient and, to
some extent, health care provider information at large,
the cRCT investigates whether this intensified approach
produces further effects. GP practices of the control
group will provide care as usual, but will have access to
the web-based campaign just like the general public.
Methods/design
Trial design
CHANGE-3 is a two-arm cRCT with GP practices and
their patients forming a cluster. It is nested within a
web-based public campaign conducted in two German re-
gions. The antibiotic prescription rates of participating
GPs will be measured over two successive winter seasons
(Fig. 1). Additionally, the quality of prescriptions in terms
of active ingredient chosen (broad- vs. narrow-spectrum
antibiotics), usage of quinolones, seasonal fluctuations,
and the knowledge of patients about antibiotics and treat-
ment of ARTI will be monitored. GP practices will be
allocated randomly either to the intervention group
(IG) or the control group (CG). In the latter, care will
be provided as usual. Claims data from the largest
German statutory health insurance provider, AOK,
will be used for all analyses. The SPIRIT checklist for
this protocol can be found in Additional file 1.
Recruitment
GP practices will be recruited in the two German states,
Mecklenburg-Western Pomerania (MV) and Baden-
Wurttemberg (BW). A total of 114 practices will be in-
cluded in the trial (38 GPs in MV and 76 GPs in BW).
GPs will be approached via invitation letters. Interested
physicians will receive trial information via telephone or
during a practice visit. Participating GPs will provide in-
formed consent in writing. They will also agree to re-
lease their patients’ anonymized prescription data as
stored by the German statutory health insurance pro-
vider AOK (§§295, 300 SGB V). These data include all
AOK-insured patients diagnosed with ARTI who receive
medical treatment during the trial. Using these data,
overall and practice-specific antibiotic prescription rates
will be determined.
In addition, two written patient surveys will be con-
ducted over two successive winter seasons. In each sur-
vey participating GP practices will recruit up to 50 ARTI
patients aged 17 years or over to fill in a questionnaire.
The questionnaire will measure patients’ knowledge of
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antibiotics as well as expectations and experiences re-
lated to antibiotic prescribing. Patients’ participation in
the survey will be anonymous and not related to any af-
filiation with a specific health insurance provider.
Exclusion criteria are: not being able to read or fill in the
questionnaire.
Intervention
The intervention is multifaceted and includes different
elements (Additional file 2). The IG will receive feedback
on practice-specific antibiotic prescription on two occa-
sions (Additional file 2, component 1) and an educa-
tional outreach visit (Additional file 2, component 2),
which is a central focus of the intervention. During the
visit, a specially trained expert will discuss the practice-
specific antibiotic-prescription feedback provided in de-
tail. Additionally, the practice will have access to
e-learning modules focusing on communication strat-
egies, e.g., on how to handle patients expecting the
prescription of antibiotics (Additional file 2, component
3 and 4). Patient information on the common cold, mid-
dle ear infections, and sinus infections is tailored to dif-
ferent groups of patients, e.g., the elderly or parents of
children with ARTI, and is provided in the form of flyers
and information on tablet computers (Additional file 2,
components 5 and 6). Communication designers will be
involved in the development of the materials.
Control
Patients of the CG will receive care as usual. Since the
cRCT will take place during the web-based public cam-
paign, GP practices of the CG will have access to the
campaign’s materials as the general public does.
Data collection, completeness and quality
Recruitment of GPs started in August 2017 and will con-
tinue until September 2018. The anonymized prescribing
data from the GPs’ patients will be retrieved at the
DOIREPYDUTS
Enrolment Allocation Post-allocation Close-out 
TIMEPOINT T0 T1 T2 
ENROLMENT: 
Eligibility screen X  
Informed consent  X  
Random Allocation  X 
INTERVENTIONS: 
prescription-
feedback  X X
educational 
outreach visit X
e-learning  
website / tablets 
flyers 
ASSESSMENTS:
antibiotic 
prescription rate
X X X X
Fig. 1 Overview of enrollment, intervention, and assessments of the CHANGE-3 trial
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beginning of the trial (baseline, T0) and over two successive
winter seasons: during the intensified intervention phase in
the first winter season (T1) and the second winter season
(T2). That means that baseline data will be retrieved retro-
spectively after provision of written informed consent by
GPs. The intervention will start after baseline collection is
completed and continue throughout the trial, due to the
public campaign running in parallel. To identify participat-
ing GPs in the secondary health data from AOK, two GP
identifiers will be collected (“Lebenslange Arztnummer”;
LANR and “Betriebsstättennummer”; BSNR). In addition,
the following information will be gathered at the start of or
during the trial: age and gender of GP, time since practice
setup, specialist title of GP, and practice characteristics, like
number of team members and field of expertise.
Also, up to 50 patient questionnaires on patient know-
ledge of antibiotics and treatment of ARTI will be delivered
by the GPs. Participation of ARTI patients is voluntary and
anonymous. This will be done throughout the entire trial.
The questionnaires will collect information on patients’
age and gender, employment situation, first language, edu-
cational background, knowledge on antibiotics, and reason
for consultation. To avoid duplicates, participants who fill
out the questionnaire will be listed anonymously (date of
questionnaire dissemination, year of birth, and gender).
Randomization
Participating GP practices will be randomly assigned in a
1:1 ratio into the two study groups after recruitment.
Randomization will be stratified by rate of antibiotic pre-
scription for ARTI at baseline per practice.
Randomization will be performed by the Institute of
Medical Biometry and Informatics at the University
Hospital Heidelberg.
Outcome measures
The primary outcome measure is the GPs’ antibiotic pre-
scription rate for ARTI at the end of the trial in com-
parison with the baseline data. These outcome data
come from routinely collected data that are provided by
the German statutory health insurance provider AOK.
Tables 1 and 2 summarize relevant Anatomical Thera-
peutic Chemical (ATC) and International Classification
of Diseases (ICD) codes, respectively, for calculating
antibiotic prescription rates.
The secondary outcome is the choice of active ingredient
(broad- vs. narrow-spectrum) in the antibiotic prescribed.
Additionally, data for the outcomes ‘patients’ level of
knowledge on antibiotics’ and ‘patients’ expectations and
experiences related to antibiotic prescribing’ are col-
lected via questionnaires in two written patient surveys.
Table 1 Relevant Anatomical Therapeutic Chemical (ATC) codes
Drug ATC code Drug group Group name
Definition of classified ATC
codes
J01FA (without
J01FA01)
Macrolides (without erythromycin) – broad-spectrum
antibiotics
Macrolides
J01DB First-generation cephalosporins Cephalosporins
J01 DC Second-generation cephalosporins Cephalosporins
J01DD Third-generation cephalosporins Cephalosporins
J01DE Fourth-generation cephalosporins Cephalosporins
J01MA Fluoroquinolones Gyrase inhibitors
J01CR Penicillins including beta-lactam inhibitors – broad-spectrum
antibiotics
Penicillins + beta-lactam-inhibitors
J01CA Penicillins with extended spectrum Penicillins with extended
spectrum
J01 CE Beta-lactamase-sensitive penicillins Beta-lactamase-sensitive penicillins
J01EE01 Sulfamethoxazole and trimethoprim Sulfamethoxazole and
trimethoprim
J01XE01 Nitrofurantoin Trimethoprim, nitrofurantoin,
fosfomycin
J01EA01 Trimethoprim Trimethoprim, nitrofurantoin,
fosfomycin
J01XX01 Fosfomycin Trimethoprim, nitrofurantoin,
fosfomycin
J01FA01 Erythromycin Erythromycin
J01FA16 Solithromycin Erythromycin
J01A Tetracyclines Tetracyclines
J01other J01-other Other antibiotics
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The surveys’ results are meant as a feedback to the prac-
tices about their patients’ perspective. The results of the
second patient survey will show, in comparison with the
first ones, whether the project interventions resulted in
changes concerning patients’ expectations and patients’
knowledge. Descriptive statistics and specific tests for
group comparison will be used to analyze survey data
(IBM SPSS statistics 20).
Methods to reduce bias and enhance data quality
With reference to the Cochrane Collaboration’s tool for
assessing risk of bias [23], a number of procedures are
carried out to reduce potential sources of bias. Firstly, to
reduce selection bias, participating GP practices in both
states are recruited with identical procedures. A
non-responder analysis will also be performed. Secondly,
randomization of participating practices will be per-
formed electronically by statisticians not involved in
physician recruitment. Thirdly, specified inclusion and
exclusion criteria (ICD and ATC codes) will be used to
calculate antibiotic prescription rates for ARTI among
participating practices in order to reduce the risk for
information bias and selective outcome reporting.
Fourthly, to reduce variation in intervention delivery,
outreach visits will be standardized. Due to financial and
time constraints within this trial it will not be possible
to blind participants and trial staff. Prior to its start, the
study was registered in the public trial archive ISRCTN.
Sample size calculation
We expect to find a relative reduction of the antibiotic
prescription rate of 30% (which means an absolute re-
duction from 40 to 28%) between the groups. The sam-
ple size considerations are based on the chi-squared test
using a significance level of α = 5% (two-sided) and a
power of (1 − β) = 80%. This results in a sample size of
n = 244 patients per group. To take the clustered struc-
ture into account, we assumed an intra-cluster correl-
ation coefficient (ICC) for patients in practices of 0.2
[24]. This value is based on previous studies. The cluster
size is assumed to be m = 80 patients. Thus, the design ef-
fect (DE) equals DE = 1 + (m − 1) × ICC = 1 + 79 × 0.2 =
16.8. These considerations result in a sample size of N = n
× DE = 244 × 16.8 = 4100 patients per group. Thus, the
total sample size is 104 practices of size m = 80 resulting in
8320 patients. A drop-out rate of about 8% is expected and,
therefore, 10 additional practices will be recruited (see Fig. 2
for detailed information on the scheduled flow of patients).
The analysis will be done by using a logistic mixed-effects
model, which we expect to explain more of the variance in
the prescription of antibiotics. Therefore, the model should
be more powerful than the chi-squared test. The calcula-
tions are done using SAS 9.4 (Proc Power).
Statistical analyses
In a first step, descriptive statistics will be provided for
the primary and secondary outcomes as well as for pa-
tient, practice, and GP characteristics, including mean,
standard deviation, median, interquartile range (IQR),
minimum and maximum for continuous variables, and
frequency in percentages for categorical variables. The
primary objective of this study is to examine the differ-
ence in antibiotic prescription rate after intervention
(T1) between the two study arms.
The confirmatory analysis of the primary endpoint will
be conducted based on the intention-to-treat (ITT) popu-
lation, where all patients will be included in the analysis
and assigned to the group they were randomized to.
A logistic mixed-effects model will be applied to assess
the respective hypothesis of equal rates in both groups
regarding the primary endpoint using a significance level
of α = 5%. A random intercept will be included for prac-
tices. Furthermore, age and gender of patients will be in-
cluded as covariates. Missing values regarding the
primary endpoint will be imputed using multiple imput-
ation. As a sensitivity analysis, the primary endpoint will
be evaluated on the per-protocol population, where pa-
tients with major protocol violations will be excluded.
As a further sensitivity analysis, the baseline prescription
rate on practice level will be included as an additional
covariate in the primary logistic mixed-effects model.
Mixed models, as described for the primary endpoint, will
be used to analyze the secondary outcomes. All calculated
p values regarding secondary endpoints will be of a descrip-
tive nature. A detailed statistical analysis plan will be writ-
ten prior to the final analysis. SAS (SAS Institute Inc., Cary,
NC, USA) version 9.4 or higher will be used to carry out
the analyses. A non-responder analysis is planned regarding
size of practice, number of antibiotic prescriptions in case
of ARTI, and application of broad-spectrum antibiotics.
Table 2 Relevant International Classification of Diseases, version 10 (ICD-10) codes
Diagnoses ICD-10 Indication ICD group
Definition of classified
ICD-10 codes
J20; J21.0; J21.1; J21.8; J21.9; J22; J40 Acute bronchitis Lower respiratory infection
J00; J02.0; J02.8; J02.9; J04; J06; J10.1; J11.1 Acute infection of the upper respiratory tract Upper respiratory infection
J01 Acute sinusitis Upper respiratory infection
J03.0; J03.8; J03.9 Tonsillitis Upper respiratory infection
H65.0; H65.1; H65.9; H66.0; H66.4; H66.9 Otitis media Upper respiratory infection
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Process evaluation
To understand the mechanisms of the educational com-
ponents, a process evaluation is accompanying the inter-
vention in the CHANGE-3 study. Using a mix of
qualitative and quantitative research methods, the process
evaluation aims at assessing reach and fidelity of the im-
plementation program, its effects on daily practice of
health care delivery to ARTI patients and the impact of di-
verse context factors on health services. The survey as
well as the interview guide used within the process evalu-
ation are based on the Theoretical Domains Framework
(TDF) [25, 26] to gain insight into working mechanisms.
The survey focuses on aspects regarding the regional
intervention with multimedia content (web-based public
campaign), the practice team intervention with outreach
visit, e-learning and feedback report and on personal per-
ceptions regarding the provision of health services to
ARTI patients. Interviews will add in-depth understanding
of educational intervention components, context factors
impacting on the uptake of the intervention and the sig-
nificance and role of the implemented set of measures to
practice teams and patients.
In the IG, data collection will occur through telephone
and face-to-face interviews with GPs, medical assistants
(GP practice nurses), patients, and outreach visitors as
well as surveys for health care providers. In the CG, pa-
tient interviews and provider surveys will be used to col-
lect data. Survey data will be collected twice. All
physicians and medical assistants in the IG and CG will
be invited to participate in the process evaluation. A
Assessed for eligibility 
n = 1450 physicians including 116000 estimated ARTI patients 
in Mecklenburg-Western Pomerania  
n = 1660 physicians including 132800 estimated ARTI patients 
in Baden-Wurttemberg 
Recruitment and Baseline documentation 
n = 38 physicians including 3040 estimated ARTI patients  
in Mecklenburg-Western Pomerania  
n = 76 physicians including 6080 estimated ARTI patients  
in Baden-Wurttemberg 
Cluster Randomization of physicians  
n = 114 
Control Group 
care as usual 
57 physicians  
including 4560 estimated ARTI patients  
Expected physician drop-out rate 8%  
52 physicians  
including 4160 estimated ARTI patients  
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Intervention Group 
on site visitation, feedback on prescription rates  
57 physicians  
including 4560 estimated ARTI patients  
Expected physician drop-out rate 8%  
52 physicians  
including 4160 estimated ARTI patients  
Fig. 2 Flow chart of the CHANGE-3 trial
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purposive sampling strategy will be followed to recruit
interview participants among GPs and medical assistants
(n = 20), patients (n = 20), and outreach visitors (n = 5).
Interviews will be recorded and transcribed. The
pre-defined categories of a framework, such as Flottorp
et al. [27] or Atkins et al. [26], will be used to identify
determinants of practice which influence health care de-
livery to ARTI patients in general practices, with regard
to the educational components of the intervention and
with regard to converting habits of antibiotic use. De-
scriptive statistics as well as specific tests for group com-
parison will be used to analyze survey data. Further
analyses which investigate the relationship between
survey-based and claims-data-based outcomes will be
applied if the sample size is sufficiently large. All col-
lected data will be pseudonymized for analysis.
The results of the process evaluation will strengthen
the reporting in CHANGE-3 and provide information
for future implementation programs.
Discussion
As a cRCT, CHANGE-3 aims at improving antibiotic
prescription among ARTI patients cared for in general
practice. The cRCT is nested in a large public campaign
that is geared towards sensitizing the population of two
German states for the reasonable use of antibiotics.
CHANGE-3 is based on two previous studies
(CHANGE and CHANGE-2) investigating the efficiency
of improved physician-patient communication, patient
empowerment and point-of-care testing on antibiotic
prescription rates [19, 24]. The study benefits from les-
sons learnt from these previous trials and, beyond that,
includes recent findings on the importance of patient in-
formation, on a practice-based approach and on the ef-
fect of practice-specific prescription feedback [28, 29].
CHANGE-3 is designed to test the hypothesis that a
relative reduction of 30% in antibiotic prescription can
be achieved by comparatively simple means.
Trial status
Recruitment of GPs will be finished in September 2018.
Recruitment of patients is ongoing throughout the trial.
Trial registration
The trial is registered at ISRCTN under the reference
ISRCTN15061174. Registered retrospectively on 13 July
2018; http://www.isrctn.com/ISRCTN15061174.
Additional files
Additional file 1: SPIRIT checklist: recommended items to address in a
clinical trial protocol. (DOCX 64 kb)
Additional file 2: Intervention description according to Template for
Intervention Description and Replication (TIDieR) [30]. (DOCX 96 kb)
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